Inventor · disambiguated record
W. Michael Kavanaugh
Also filed as: KAVANAUGH W M · KAVANAUGH W MICHAEL
19 granted patents·19 pending applications·418 citations·filing 1997–2023
94Inventor score
Files withCHIRON CORP10CYTOMX THERAPEUTICS INC7NOVARTIS VACCINES & DIAGNOSTIC6FIVE PRIME THERAPEUTICS INC3BRENNAN THOMAS2
Top patents by PatentIndex Score
38 records- 0197US7476506B2Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancersNOVARTIS VACCINES & DIAGNOSTIC·Filed 2007·Granted Jan 13, 2009·150 cites·17 claims
- 0296US7198899B2Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancersCHIRON CORP·Filed 2003·Granted Apr 3, 2007·142 cites·3 claims
- 0394US6656728B1Fibroblast growth factor receptor-immunoglobulin fusionCHIRON CORP·Filed 2000·Granted Dec 2, 2003·57 cites·13 claims
- 0491US7511019B2Method of treating coronary artery disease by administering FGF-4NOVARTIS VACCINES & DIAGNOSTIC·Filed 2005·Granted Mar 31, 2009·6 cites·11 claims
- 0588US6825333B1EGFH2 genes and gene productsCHIRON CORP·Filed 2000·Granted Nov 30, 2004·15 cites·8 claims
- 0686US8445445B2Method of promoting hair growth using FGFR4 extracellular domainsBRENNAN THOMAS·Filed 2010·Granted May 21, 2013·7 cites·22 claims
- 0785US7858584B2Angiogenically effective unit dose of FGF and method of administeringNOVARTIS VACCINES & DIAGNOSTIC·Filed 2009·Granted Dec 28, 2010·2 cites·19 claims
- 0881US8685931B2Hair growth methods using FGFR3 extracellular domainsBRENNAN THOMAS·Filed 2010·Granted Apr 1, 2014·6 cites·41 claims
- 0980US8614183B2Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2HARDING THOMAS·Filed 2010·Granted Dec 24, 2013·6 cites·11 claims
- 1072US7276587B2Antibodies to EGFH2 polypeptidesCHIRON CORP·Filed 2004·Granted Oct 2, 2007·2 cites·2 claims
- 1170US9149507B2Method of treating coronary artery disease by administering FGF-9NOVARTIS VACCINES & DIAGNOSTIC·Filed 2013·Granted Oct 6, 2015·0 cites·11 claims
- 1270US8178493B2Method for inducing angiogenesis in a heart of a patientHUNG DAVID T·Filed 2009·Granted May 15, 2012·0 cites·4 claims
- 1367US7265089B2KGF polypeptide compositionsCHIRON CORP·Filed 2002·Granted Sep 4, 2007·3 cites·19 claims
- 1466US8618052B2Method of treating coronary artery disease by administering FGF-5WHITEHOUSE MARTHA J·Filed 2010·Granted Dec 31, 2013·1 cites·11 claims
- 1566US2018221446A1Angiogenically Effective Unit Dose Of FGF And Method Of AdministeringNOVARTIS VACCINES & DIAGNOSTICS INC·Filed 2017·Application pending·0 cites
- 1665US9169313B2Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteinsFIVE PRIME THERAPEUTICS INC·Filed 2013·Granted Oct 27, 2015·0 cites·22 claims
- 1763US7705117B2EGFH2 genes and gene productsCHIRON CORP·Filed 2007·Granted Apr 27, 2010·0 cites·12 claims
- 1861US2025333487A1Activatable dual-anchored masked molecules and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1958US2008008711A1Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancersSCHLEYER SIEW C·Filed 2007·Application pending·0 cites
- 2058US2023174995A1Activatable polypeptide complexCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2158US2023183382A1Activatable polypeptide complexCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2256US6090621ASignaling inositol polyphosphate 5-phosphatases (SIPs)CHIRON CORP·Filed 1998·Granted Jul 18, 2000·16 cites·6 claims
- 2353US2008200378A1KGF polypeptide compositionsNOVARTIS VACCINES & DIAGNOSTIC·Filed 2007·Application pending·0 cites
- 2452US2019117789A1Activatable anti-cd166 antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2552US2016120943A1Angiogenically effective unit dose of fgf and method of administeringNOVARTIS VACCINES & DIAGNOSTIC·Filed 2015·Application pending·0 cites
- 2652US2021100913A1Activatable anti-cd166 antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2752US2006281679A1Human FGF-23 gene and gene expression productsITOH NOBUYUKI·Filed 2005·Application pending·0 cites
- 2851US7531511B2Method for inducing angiogenesis or vascular perfusion in the myocardium comprising administering FGF-2NOVARTIS VACCINES & DIAGNOSTICS INC·Filed 2005·Granted May 12, 2009·0 cites·6 claims
- 2950US2004063910A1Fibroblast growth factorCHIRON CORP·Filed 2003·Application pending·0 cites
- 3050US2021020264A1Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjectsCYTOMX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3150US2014274898A1Hair growth methods using fgfr3 extracellular domainsFIVE PRIME THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3249US2004091898A1PI 3-kinase fusion mutants and uses thereofFiled 2003·Application pending·0 cites
- 3347US2003171294A1Dose of an angiogenic factor and method of administering to improve myocardial blood flowCHIRON CORP·Filed 2003·Application pending·0 cites
- 3446US2022023439A1Activatable anti-cd166 antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3545US2002082205A1Human FGF-23 gene and gene expression productsFiled 2001·Application pending·0 cites
- 3639US2003105302A1Human FGF-23 gene and gene expression productsFiled 2001·Application pending·0 cites
- 3736US6613956B1PI 3-kinase fusion mutants and uses thereofCHIRON CORP·Filed 1997·Granted Sep 2, 2003·5 cites·4 claims
- 3836US2018016555A1Slamf1 antagonists and uses thereofFIVE PRIME THERAPEUTICS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when W. Michael Kavanaugh files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →